A GlaxoSmithKline building in London is shown in 2013.
“In the course of its ongoing inquiry, the SFO has requested additional information from the group regarding third-party advisers engaged by the company,” Glaxo said Wednesday in a securities filing. The company said it informed the U.S. Securities and Exchange Commission and Department of Justice of the SFO’s inquiry, and is “responding to their requests for additional information.”
Glaxo in September 2016 agreed to pay the SEC $20 million to settle civil charges it violated the Foreign Corrupt Practices Act, an anti-bribery law, when its Chinese units paid health-care professionals to prescribe its drugs. Glaxo didn’t admit or deny wrongdoing but agreed to provide the SEC with updates for two years on its efforts to improve its compliance systems, the SEC said.
Also in 2016, the Justice Department concluded an investigation of its own and said it would take no further action, a Glaxo spokeswoman said via email on Wednesday.
The SEC and Justice Department declined to comment. The SFO didn’t immediately respond to a request for comment after U.K. business hours.
Glaxo said it couldn’t estimate the potential financial effect of the issue and hadn’t made any provision for them in its accounts.
Write to Henry Cutter at Henry.Cutter@wsj.com. Follow him on Twitter at @henry_cutter.